Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Lymphoma | Review

Targeting CD47 for cancer immunotherapy

Authors: Zhongxing Jiang, Hao Sun, Jifeng Yu, Wenzhi Tian, Yongping Song

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Abstract

Much progress has been made in targeting CD47 for cancer immunotherapy in solid tumors (ST) and hematological malignancies. We summarized the CD47-related clinical research and analyzed the research trend both in the USA and in China. As of August 28, 2021, there are a total 23 related therapeutic agents with 46 clinical trials in the NCT registry platform. Among these trials, 29 are in ST, 14 in hematological malignancies and 3 in both solid tumor and hematological malignancy. The ST include gastric cancer, head and neck squamous cell carcinoma and leiomyosarcoma, while the hematological malignancies include non-Hodgkin's lymphoma, acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and chronic myeloid leukemia. Majority of the CD47-related clinical trials are at the early phases, such as 31 at phase I, 14 at phase II and 1 at phase III in the USA and 9, 6, 1, in China, respectively. The targets and spectrums of mechanism of action include 26 with mono-specific and 20 with bi-specific targets in the USA and 13 with mono-specific and 3 with bi-specific targets in China. The new generation CD47 antibodies have demonstrated promising results, and it is highly hopeful that some candidate agents will emerge and make into clinical application to meet the urgent needs of patients.
Literature
1.
Arrieta O, Aviles-Salas A, Orozco-Morales M, Hernández-Pedro N, Cardona AF, Cabrera-Miranda L, et al. Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non-small cell lung cancer. Cancer Med. 2020;9(7):2390–402.PubMedPubMedCentralCrossRef
2.
Shi M, Gu Y, Jin K, Fang H, Chen Y, Cao Y, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration. Cancer Immunol Immunother CII. 2021;70(7):1831–40.PubMedCrossRef
3.
Kim H, Jee S, Kim Y, Sim J, Bang S, Son HK, et al. Correlation of CD47 expression with adverse clinicopathologic features and an unfavorable prognosis in colorectal adenocarcinoma. Diagnostics (Basel, Switzerland). 2021;11(4):668.
4.
Imam R, Chang Q, Black M, Yu C, Cao W. CD47 expression and CD163(+) macrophages correlated with prognosis of pancreatic neuroendocrine tumor. BMC Cancer. 2021;21(1):320.PubMedPubMedCentralCrossRef
5.
Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci USA. 2017;114(49):E10578–85.PubMedPubMedCentralCrossRef
6.
Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Can Res. 2011;71(4):1374–84.CrossRef
7.
Orozco-Morales M, Avilés-Salas A, Hernández-Pedro N, Catalán R, Cruz-Rico G, Colín-González AL, et al. Clinicopathological and prognostic significance of CD47 expression in lung neuroendocrine tumors. J Immunol Res. 2021;2021:6632249.PubMedPubMedCentralCrossRef
8.
Andrejeva G, Capoccia BJ, Hiebsch RR, Donio MJ, Darwech IM, Puro RJ, et al. Novel SIRPα antibodies that induce single-agent phagocytosis of tumor cells while preserving T cells. J Immunol (Baltimore, Md: 1950). 2021;206(4):712–21.CrossRef
9.
Sikic BI, Lakhani N, Patnaik A, Shah SA, Chandana SR, Rasco D, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019;37(12):946–53.PubMedPubMedCentralCrossRef
10.
Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–21.PubMedPubMedCentralCrossRef
11.
12.
Sallman DA, Donnellan WB, Asch AS, et al. The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: initial phase 1b results. J Clin Oncol. 2019;37(15_suppl):7009.CrossRef
13.
Fujioka Y, Matozaki T, Noguchi T, Iwamatsu A, Yamao T, Takahashi N, et al. A novel membrane glycoprotein, SHPS-1, that binds the SH2-domain-containing protein tyrosine phosphatase SHP-2 in response to mitogens and cell adhesion. Mol Cell Biol. 1996;16(12):6887–99.PubMedPubMedCentralCrossRef
14.
Oshima K, Ruhul Amin AR, Suzuki A, Hamaguchi M, Matsuda S. SHPS-1, a multifunctional transmembrane glycoprotein. FEBS Lett. 2002;519(1–3):1–7.PubMedCrossRef
15.
Timms JF, Swanson KD, Marie-Cardine A, Raab M, Rudd CE, Schraven B, et al. SHPS-1 is a scaffold for assembling distinct adhesion-regulated multi-protein complexes in macrophages. Curr Biol CB. 1999;9(16):927–30.PubMedCrossRef
16.
Johansen ML, Brown EJ. Dual regulation of SIRPalpha phosphorylation by integrins and CD47. J Biol Chem. 2007;282(33):24219–30.PubMedCrossRef
17.
Adams S, van der Laan LJ, Vernon-Wilson E, Renardel de Lavalette C, Döpp EA, Dijkstra CD, et al. Signal-regulatory protein is selectively expressed by myeloid and neuronal cells. J Immunol (Baltimore, Md: 1950). 1998;161(4):1853–9.CrossRef
18.
Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol. 2001;11(3):130–5.PubMedCrossRef
19.
20.
Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci. 1995;108(Pt 11):3419–25.PubMedCrossRef
21.
Jiang P, Lagenaur CF, Narayanan V. Integrin-associated protein is a ligand for the P84 neural adhesion molecule. J Biol Chem. 1999;274(2):559–62.PubMedCrossRef
22.
Lindberg FP, Gresham HD, Reinhold MI, Brown EJ. Integrin-associated protein immunoglobulin domain is necessary for efficient vitronectin bead binding. J Cell Biol. 1996;134(5):1313–22.PubMedCrossRef
23.
Vernon-Wilson EF, Kee WJ, Willis AC, Barclay AN, Simmons DL, Brown MH. CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Eur J Immunol. 2000;30(8):2130–7.PubMedCrossRef
24.
Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA, et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem. 2000;275(48):37984–92.PubMedCrossRef
25.
Yamao T, Noguchi T, Takeuchi O, Nishiyama U, Morita H, Hagiwara T, et al. Negative regulation of platelet clearance and of the macrophage phagocytic response by the transmembrane glycoprotein SHPS-1. J Biol Chem. 2002;277(42):39833–9.PubMedCrossRef
26.
27.
Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–85.PubMedPubMedCentralCrossRef
28.
29.
Kojima Y, Volkmer JP, McKenna K, Civelek M, Lusis AJ, Miller CL, et al. CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis. Nature. 2016;536(7614):86–90.PubMedPubMedCentralCrossRef
30.
Wernig G, Chen SY, Cui L, Van Neste C, Tsai JM, Kambham N, et al. Unifying mechanism for different fibrotic diseases. Proc Natl Acad Sci USA. 2017;114(18):4757–62.PubMedPubMedCentralCrossRef
31.
Li Z, Li Y, Gao J, Fu Y, Hua P, Jing Y, et al. The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy. Life Sci. 2021;273:119150.PubMedCrossRef
32.
Noman MZ, Van Moer K, Marani V, Gemmill RM, Tranchevent LC, Azuaje F, et al. CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. Oncoimmunology. 2018;7(4):e1345415.PubMedPubMedCentralCrossRef
33.
Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, et al. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci USA. 2015;112(45):E6215–23.PubMedPubMedCentralCrossRef
34.
Kaur S, Cicalese KV, Bannerjee R, Roberts DD. Preclinical and clinical development of therapeutic antibodies targeting functions of CD47 in the tumor microenvironment. Antibody Ther. 2020;3(3):179–92.CrossRef
35.
Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, et al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol. 2019;9:1380.PubMedCrossRef
36.
37.
Bruce LJ, Ghosh S, King MJ, Layton DM, Mawby WJ, Stewart GW, et al. Absence of CD47 in protein 4.2-deficient hereditary spherocytosis in man: an interaction between the Rh complex and the band 3 complex. Blood. 2002;100(5):1878–85.PubMedCrossRef
38.
Lindberg FP, Gresham HD, Schwarz E, Brown EJ. Molecular cloning of integrin-associated protein: an immunoglobulin family member with multiple membrane-spanning domains implicated in alpha v beta 3-dependent ligand binding. J Cell Biol. 1993;123(2):485–96.PubMedCrossRef
39.
Kaur S, Kuznetsova SA, Pendrak ML, Sipes JM, Romeo MJ, Li Z, et al. Heparan sulfate modification of the transmembrane receptor CD47 is necessary for inhibition of T cell receptor signaling by thrombospondin-1. J Biol Chem. 2011;286(17):14991–5002.PubMedPubMedCentralCrossRef
40.
Dahl KN, Westhoff CM, Discher DE. Fractional attachment of CD47 (IAP) to the erythrocyte cytoskeleton and visual colocalization with Rh protein complexes. Blood. 2003;101(3):1194–9.PubMedCrossRef
41.
McDonald JF, Zheleznyak A, Frazier WA. Cholesterol-independent interactions with CD47 enhance alphavbeta3 avidity. J Biol Chem. 2004;279(17):17301–11.PubMedCrossRef
42.
Peluso MO, Adam A, Armet CM, Zhang L, O’Connor RW, Lee BH, et al. The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. J Immunother Cancer. 2020;8(1):e000413.PubMedPubMedCentralCrossRef
43.
Upton R, Banuelos A, Feng D, Biswas T, Kao K, McKenna K, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci USA. 2021;118(29):e2026849118.PubMedPubMedCentralCrossRef
44.
Kuo TC, Chen A, Harrabi O, Sockolosky JT, Zhang A, Sangalang E, et al. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol. 2020;13(1):160.PubMedPubMedCentralCrossRef
45.
Zhang Z, Luo F, Cao J, Lu F, Zhang Y, Ma Y, et al. Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China. J Hematol Oncol. 2021;14(1):124.PubMedPubMedCentralCrossRef
46.
Dheilly E, Majocchi S, Moine V, Didelot G, Broyer L, Calloud S, et al. Tumor-directed blockade of CD47 with bispecific antibodies induces adaptive antitumor immunity. Antibodies (Basel, Switzerland). 2018;7(1):3.
47.
Lu Q, Chen X, Wang S, Lu Y, Yang C, Jiang G. Potential new cancer immunotherapy: anti-CD47-SIRPα antibodies. OncoTargets Ther. 2020;13:9323–31.CrossRef
48.
Russ A, Hua AB, Montfort WR, Rahman B, Riaz IB, Khalid MU, et al. Blocking “don’t eat me” signal of CD47-SIRPα in hematological malignancies, an in-depth review. Blood Rev. 2018;32(6):480–9.PubMedPubMedCentralCrossRef
49.
50.
Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE. 2015;10(9):e0137345.PubMedPubMedCentralCrossRef
51.
Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia. Mol Cancer Ther. 2018;17(8):1739–51.PubMedPubMedCentralCrossRef
52.
Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, et al. TTI-621 (SIRPαFc): a CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res. 2017;23(4):1068–79.PubMedCrossRef
53.
Velliquette RW, Aeschlimann J, Kirkegaard J, Shakarian G, Lomas-Francis C, Westhoff CM. Monoclonal anti-CD47 interference in red cell and platelet testing. Transfusion. 2019;59(2):730–7.PubMedCrossRef
54.
Advani R, Bartlett NL, Smith SM, Roschewski M, Popplewell L, Flinn I, Collins G, Ghosh N, LaCasce A, Asch A, Kline J, Kesevan M, Tran T, Lynn J, Huang J, Agoram B, Volkmer J, Takimoto CH, Chao MP, Mehta A. The first-in-class anti-CD47 antibody HU5F9-G4 + rituximab induces durable responses in relapsed/refractory DLBCL and indolent lymphoma: interim phase 1B/2 results. Hematol Oncol. 2019;37(S2):89–90. https://​doi.​org/​10.​1002/​hon57_​2629.CrossRef
55.
Ansell SM, Maris MB, Lesokhin AM, Chen RW, Flinn IW, Sawas A, et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27(8):2190–9.PubMedCrossRef
56.
Uger R, Johnson L. Blockade of the CD47-SIRPα axis: a promising approach for cancer immunotherapy. Expert Opin Biol Ther. 2020;20(1):5–8.PubMedCrossRef
57.
Krish Patel MBM, Bruce D. Cheson, Jeffrey A. Zonder, Alexander M. Lesokhin, Gottfried Von Keudell, Erlene Kuizon Seymour, Gloria H.Y. Lin, Tina Catalano, Yaping Shou, Swaminathan Padmanabhan Iyer, Radhakrishnan Ramchandren. Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma. 2020. https://​meetings.​asco.​org/​abstracts-presentations/​188624.
58.
Lisa Johnson RKP, Rebecca L. King, Stephen Maxted Ansell, Robert W. Chen, Ian Flinn, Michael B. Maris, Meghan Irwin, Eric L. Sievers, Penka S. Petrova, Robert A. Uger. Effects of TTI-621 (SIRPαFc) on CD47 and serum cytokines associated with phagocytosis in subjects with relapsed, refractory hematologic malignancies: pharmacodynamic findings from a first-in-human clinical trial. ASCO meeting abstract. 2017. https://​meetings.​asco.​org/​abstracts-presentations/​140876.
59.
Kim TM, Lakhani N, Gainor J, Kamdar M, Fanning P, Squifflet P, Jin F, Wan H, Pons J, Randolph SS, Kim WS. A phase 1 study of ALX148, a CD47 blocker, in combination with rituximab in patients with non-Hodgkin lymphoma. Blood. 2019;134(Supplement_1):1953.CrossRef
60.
Kauder SE, Kuo TC, Harrabi O, Chen A, Sangalang E, Doyle L, et al. ALX148 blocks CD47 and enhances innate and adaptive antitumor immunity with a favorable safety profile. PLoS ONE. 2018;13(8):e0201832.PubMedPubMedCentralCrossRef
61.
Chow LQMGJ, Lakhani NJ, et al. A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy. J Clin Oncol. 2019;37(15_suppl):2514.CrossRef
62.
Chow LQM, Gainor JF, Lakhani NJ, Lee KW, Chung HC, Lee J, LoRusso P, Bang Y-J, Hodi FS, Davila RS, Fanning P, Squifflet P, Jin F, Wan H, Kuo T, Pons J, Randolph S, Messersmith WA. A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy. 2020. https://​meetings.​asco.​org/​abstracts-presentations/​189180.
63.
64.
Puro RJ, Bouchlaka MN, Hiebsch RR, Capoccia BJ, Donio MJ, Manning PT, et al. Development of AO-176, a next-generation humanized anti-CD47 antibody with novel anticancer properties and negligible red blood cell binding. Mol Cancer Ther. 2020;19(3):835–46.PubMedCrossRef
65.
Burris HA III AIS, Taylor MH, Yeku OO, Liu JF, Munster PN, Hamilton EP, Thomas JS, Gatlin F, Penson RT, Abrams TA, Dhawan MS, Walling JM, Frye JW, Romanko K, Sung V, Brachmann C, El-Khoueiry AB. A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors. 2021. https://​meetings.​asco.​org/​abstracts-presentations/​199338.
66.
67.
Champiat S, Kotecki N, Korakis I, Vinceneux A, Jungels C, Blatchford J, Elgadi MM, Clarke N, Fromond C, Poirier N, Vasseur B, Marabelle A, Delord J-P. Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRPα inhibitor: results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors. 2021. https://​meetings.​asco.​org/​abstracts-presentations/​196073.
68.
69.
70.
Qi J, Li J, Jiang B, Jiang B, Liu H, Cao X, Zhang M, Meng Y, Xiaoyu MA, Jia Y, Guo J. A phase I/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase i results. Blood. 2020;136(Supplement 1):30–1. https://​doi.​org/​10.​1182/​blood-2020-134391.CrossRef
71.
72.
Wang Y, Pan D, Huang C, Chen B, Li M, Zhou S, et al. Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody. MAbs. 2020;12(1):1748322.PubMedPubMedCentralCrossRef
73.
Wang Y, Ni H, Zhou S, He K, Gao Y, Wu W, et al. Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity. Cancer Immunol Immunother CII. 2021;70(2):365–76.PubMedCrossRef
74.
75.
76.
77.
Gao Y, Zhang D, Yang C, Duan X, Li X, Zhong D. Two validated liquid chromatography-mass spectrometry methods with different pretreatments for the quantification of an anti-CD47 monoclonal antibody in rat and cynomolgus monkey serum compared with an electrochemiluminescence method. J Pharm Biomed Anal. 2019;175:112792.PubMedCrossRef
78.
79.
Zhao W, Hu X, Li W, Li R, Chen J, Zhou L, et al. M2-like TAMs function reversal contributes to breast cancer eradication by combination dual immune checkpoint blockade and photothermal therapy. Small. 2021;17(13):e2007051.PubMedCrossRef
80.
Chen SH, Dominik PK, Stanfield J, Ding S, Yang W, Kurd N, et al. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity. J Immunother Cancer. 2021;9(10):e003464.PubMedPubMedCentralCrossRef
81.
82.
83.
Anniss AM, Sparrow RL. Expression of CD47 (integrin-associated protein) decreases on red blood cells during storage. Transfus Apheresis Sci. 2002;27(3):233–8.CrossRef
84.
Khandelwal S, van Rooijen N, Saxena RK. Reduced expression of CD47 during murine red blood cell (RBC) senescence and its role in RBC clearance from the circulation. Transfusion. 2007;47(9):1725–32.PubMedCrossRef
85.
Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer (Oxford, England: 1990). 2017;76:100–9.CrossRef
86.
Barclay AN, Brown MH. The SIRP family of receptors and immune regulation. Nat Rev Immunol. 2006;6(6):457–64.PubMedCrossRef
87.
Logtenberg MEW, Jansen JHM, Raaben M, Toebes M, Franke K, Brandsma AM, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and a target for cancer immunotherapy. Nat Med. 2019;25(4):612–9.PubMedPubMedCentralCrossRef
88.
Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2019;14(1):89–97.PubMedCrossRef
89.
Liu Q, Wen W, Tang L, Qin CJ, Lin Y, Zhang HL, et al. Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity. Oncoimmunology. 2016;5(9):e1183850.PubMedPubMedCentralCrossRef
90.
Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, et al. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. J Hematol Oncol. 2021;14(1):155.PubMedPubMedCentralCrossRef
Metadata
Title
Targeting CD47 for cancer immunotherapy
Authors
Zhongxing Jiang
Hao Sun
Jifeng Yu
Wenzhi Tian
Yongping Song
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-021-01197-w

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Correction

Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine

Research

Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia

Letter to the Editor

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Letter to the Editor

A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia

Letter to the Editor

Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

Review

Targeting hypoxic tumor microenvironment in pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits